Related Experiment Videos
Renal cell carcinoma: current status and future prospects
1Greenwich Hospital, 77 Lafayette Place, Greenwich, CT 06830, USA. bevdruck@hotmail.com
Cancer Treatment Reviews
|October 21, 2005
Summary
Renal cell carcinoma (RCC) is increasing, with advanced stages often refractory. New targeted therapies show promise for treating this kidney cancer, improving outcomes beyond current treatments like immunotherapy.
Area of Science:
- Oncology
- Urology
- Nephrology
Background:
- The incidence of renal cell carcinoma (RCC) is rising globally.
- While localized RCC management has improved, advanced RCC remains refractory with a poor prognosis.
- Early detection and characterization of renal tumors enable less invasive treatments for localized disease.
Purpose of the Study:
- To review current treatment strategies for renal cell carcinoma (RCC).
- To highlight challenges in managing advanced RCC.
- To discuss emerging molecularly targeted therapies for RCC.
Main Methods:
- Literature review of current and developing treatments for renal cell carcinoma.
- Analysis of diagnostic advancements and surgical techniques.
- Examination of systemic therapies including immunotherapy and targeted agents.
Main Results:
- Minimally invasive nephrectomy techniques are increasingly preferred for localized RCC.
- Standard treatments for advanced RCC, including cytokine immunotherapy, have limited success and poor tolerance.
- Understanding RCC pathophysiology has identified molecular targets for novel therapies.
Conclusions:
- Despite advances, effective treatments for advanced renal cell carcinoma are limited.
- Emerging targeted therapies hold promise for improving outcomes in advanced RCC.
- Continued research into RCC molecular pathways is crucial for developing better treatments.